Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 2.5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 2.5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 5mg - lenalidomide (lenalidomide hydrochloride monohydrate) 5mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 10mg - lenalidomide (lenalidomide hydrochloride monohydrate) 10mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 15mg - lenalidomide (lenalidomide hydrochloride monohydrate) 15mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 20mg - lenalidomide (lenalidomide hydrochloride monohydrate) 20mg

Canada - English - Health Canada

teva canada limited - lenalidomide (lenalidomide hydrochloride monohydrate) - capsule - 25mg - lenalidomide (lenalidomide hydrochloride monohydrate) 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: gelatin; lactose; shellac; croscarmellose sodium; microcrystalline cellulose; indigo carmine; magnesium stearate; propylene glycol; potassium hydroxide; titanium dioxide; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: lactose; titanium dioxide; iron oxide yellow; gelatin; microcrystalline cellulose; croscarmellose sodium; propylene glycol; shellac; potassium hydroxide; magnesium stearate; indigo carmine; iron oxide black - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia,due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic,abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle,cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: magnesium stearate; lactose; potassium hydroxide; propylene glycol; gelatin; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide black; shellac - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lenalidomide, quantity: 25 mg - capsule - excipient ingredients: propylene glycol; croscarmellose sodium; titanium dioxide; lactose; gelatin; microcrystalline cellulose; iron oxide black; shellac; potassium hydroxide; magnesium stearate - multiple myeloma (mm),lenalidomide sandoz is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide sandoz is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl),lenalidomide sandoz is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.